Detalles de la búsqueda
1.
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Lancet
; 398(10315): 1984-1996, 2021 11 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34767764
2.
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
Curr Ther Res Clin Exp
; 93: 100601, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32983284
3.
Application of Resource Utilization in Dementia (RUD) instrument in a global setting.
Alzheimers Dement
; 9(4): 429-435.e17, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23142433
4.
Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib.
Arthritis Res Ther
; 23(1): 94, 2021 03 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33766074
5.
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.
Lancet Rheumatol
; 3(4): e270-e283, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279411
6.
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD.
Dermatol Ther (Heidelb)
; 11(1): 221-233, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33382444
7.
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Lancet Rheumatol
; 3(1): e28-e39, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38273637
8.
Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States.
J Manag Care Spec Pharm
; 26(8): 1027-1038, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32308099
9.
Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study.
Patient Prefer Adherence
; 14: 949-961, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32606613
10.
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
RMD Open
; 6(1)2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32396519
11.
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Rheumatol Ther
; 7(3): 553-580, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32506317
12.
Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.
J Patient Rep Outcomes
; 3(1): 30, 2019 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31111255
13.
Retraction Note to: Content validity and psychometric evaluation of functional assessment of chronic illness therapy-fatigue in patients with psoriatic arthritis.
J Patient Rep Outcomes
; 3(1): 32, 2019 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31139969
14.
Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.
J Patient Rep Outcomes
; 3(1): 5, 2019 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30680661
15.
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
RMD Open
; 5(1): e000806, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30713721
16.
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
RMD Open
; 5(1): e000808, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30713722
17.
Psychometric validation of the cancer therapy satisfaction questionnaire.
Value Health
; 11(4): 669-79, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18194397
18.
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Arthritis Res Ther
; 20(1): 242, 2018 Oct 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373651
19.
Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint Analysis.
Am Health Drug Benefits
; 11(8): 408-417, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30647828
20.
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD.
Dermatol Ther (Heidelb)
; 11(4): 1449-1450, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34181217